Zanubrutinib

Class
Targeted therapy
Subclass
Bruton tyrosine kinase inhibitors
Substance name
Zanubrutinib
Brand names
Brukinsa®
Common formulations
Gelatin-coated capsule
Dosage and administration
Adults patients
Chronic lymphocytic leukemia
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Follicular lymphoma • Relapsed or refractory, received ≥ 2 prior lines of systemic therapy
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Administered in combination with obinutuzumab.
Mantle cell lymphoma • Received at least one prior therapy
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Marginal zone lymphoma • Relapsed or refractory, received at least one anti-CD20-based regimen
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Small lymphocytic lymphoma
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Waldenstrom's macroglobulinemia
•
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Indications for use
Labeled indications
Adults
•
Treatment of Waldenstrom's macroglobulinemia
•
Treatment of chronic lymphocytic leukemia
•
Treatment of follicular lymphoma (relapsed or refractory, received ≥ 2 prior lines of systemic therapy)
•
Treatment of mantle cell lymphoma (received at least one prior therapy)
•
Treatment of marginal zone lymphoma (relapsed or refractory, received at least one anti-CD20-based regimen)
•
Treatment of small lymphocytic lymphoma
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource